The designation covers use of the wearable device in patients aged 22 years and older who are being treated in the intensive care unit following an aneurysm-related brain hemorrhage. The technology is intended to complement standard clinical care by lowering the risk of cerebral vasospasm, a serious complication that can develop days after the initial bleeding event.

Addressing a Major Unmet Need in Neurocritical Care

Aneurysmal subarachnoid hemorrhage occurs when a ruptured intracranial aneurysm causes bleeding into the space surrounding the brain. Although many patients survive the initial hemorrhage, they remain vulnerable to secondary complications, particularly cerebral vasospasm. This condition involves narrowing of cerebral blood vessels, which can restrict blood flow and lead to additional neurological damage, disability, or death.

Current treatment strategies are largely aimed at managing symptoms and maintaining adequate cerebral perfusion. Standard care typically includes administration of nimodipine, the only medication proven to improve outcomes in this patient population, along with intensive hemodynamic monitoring and support. In severe or treatment-resistant cases, patients may require invasive endovascular procedures such as balloon angioplasty or catheter-based delivery of vasodilator drugs.

Despite these interventions, cerebral vasospasm continues to be a leading contributor to poor outcomes after subarachnoid hemorrhage.

How the V-Link System Works

The V-Link System uses low-level electrical stimulation delivered through the outer ear to activate a branch of the vagus nerve. By targeting vagal pathways, the device is designed to influence inflammatory processes that are believed to play a significant role in secondary brain injury following hemorrhagic stroke and other critical illnesses.

Unlike invasive neuromodulation approaches, V-Link can be deployed at the bedside and does not require surgical implantation. Aurenar believes the technology may offer a way to address some of the underlying biological mechanisms associated with post-hemorrhage complications rather than focusing solely on blood vessel constriction.

According to Aurenar founder and CEO Dr. Eric Leuthardt, a professor of neurosurgery at Washington University School of Medicine in St. Louis, treatment options for cerebral vasospasm have changed little over recent decades and remain largely supportive. He noted that many patients continue to experience significant morbidity despite existing therapies, highlighting the need for new approaches that can be introduced early in the ICU setting.

Growing Momentum for Neurotechnology Innovation

Aurenar’s latest regulatory milestone reflects broader momentum in the neurotechnology sector, where companies developing wearable, implantable, and bedside neurological devices are increasingly advancing through FDA pathways.

Recent examples include CorTec’s Brain Interchange system, which received FDA Breakthrough Device designation for a brain-computer interface intended to support motor recovery in individuals with chronic stroke-related impairments. BrainSpace also secured FDA 510(k) clearance for its Intellidrop cerebrospinal fluid management platform, while Ceribell and Naox Technologies achieved regulatory progress for stroke-monitoring and in-ear EEG technologies, respectively.

Investor interest in neuromodulation platforms remains strong as well. Earlier this year, Cognito Therapeutics raised substantial funding to further develop its noninvasive neurostimulation technology for Alzheimer’s disease, another area where FDA Breakthrough Device designation has helped accelerate innovation.

With the V-Link System now granted Breakthrough Device status, Aurenar is positioned to work more closely with the FDA as it advances development of a potential new option for preventing one of the most dangerous complications associated with aneurysmal subarachnoid hemorrhage.